Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells--brief report

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2640-3. doi: 10.1161/ATVBAHA.112.300317. Epub 2012 Sep 20.

Abstract

Objective: The endothelial response elicited by the G-protein-coupled receptor pathway involving apelin and APJ predicts an overall vasoprotective effect. As a number of downstream endothelial targets of apelin/APJ signaling are also known to be targeted by statins (3-hydroxy-3-methyl-glutaryl [HMG]-CoA reductase inhibitors) as potential mediators of their known pleiotropic effects, we evaluated for the involvement of apelin/APJ signaling in statin endothelial effects.

Methods and results: We found that disruption of apelin/APJ signaling in endothelial cells leads to significantly decreased expression of Krűppel-like factor 2, endothelial nitric oxide synthase, and thrombomodulin. We found that statin-mediated induction of Krűppel-like factor 2, endothelial nitric oxide synthase, and thrombomodulin expression, as well as inhibition of monocyte-endothelial adhesion, was abrogated by concurrent apelin knockdown. Moreover, we found that statins can transcriptionally regulate APJ in a Krűppel-like factor 2-dependent manner, demonstrating the presence of a positive-feedback loop.

Conclusions: Our findings provide a novel mechanism by which the apelin/APJ pathway serves as a critical intermediary that links statin to its pleiotropic effects in regulating endothelial gene targets and function.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipokines
  • Animals
  • Apelin
  • Apelin Receptors
  • COS Cells
  • Cell Adhesion / drug effects
  • Chlorocebus aethiops
  • Coculture Techniques
  • Fatty Acids, Monounsaturated / pharmacology
  • Fluorobenzenes / pharmacology
  • Fluvastatin
  • Gene Expression Regulation / drug effects
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / immunology
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Indoles / pharmacology
  • Intercellular Signaling Peptides and Proteins / deficiency
  • Intercellular Signaling Peptides and Proteins / genetics
  • Intercellular Signaling Peptides and Proteins / metabolism*
  • Kruppel-Like Transcription Factors / genetics
  • Kruppel-Like Transcription Factors / metabolism
  • Mice
  • Mice, Knockout
  • Monocytes / drug effects
  • Monocytes / immunology
  • Monocytes / metabolism
  • Nitric Oxide Synthase Type III / genetics
  • Nitric Oxide Synthase Type III / metabolism
  • Pyrimidines / pharmacology
  • RNA Interference
  • Receptors, G-Protein-Coupled / drug effects*
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism
  • Rosuvastatin Calcium
  • Signal Transduction / drug effects*
  • Simvastatin / pharmacology
  • Sulfonamides / pharmacology
  • Thrombomodulin / genetics
  • Thrombomodulin / metabolism
  • Time Factors
  • Transfection

Substances

  • APLN protein, human
  • APLNR protein, human
  • Adipokines
  • Apelin
  • Apelin Receptors
  • Apln protein, mouse
  • Aplnr protein, mouse
  • Fatty Acids, Monounsaturated
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Intercellular Signaling Peptides and Proteins
  • KLF2 protein, human
  • Klf2 protein, mouse
  • Kruppel-Like Transcription Factors
  • Pyrimidines
  • Receptors, G-Protein-Coupled
  • Sulfonamides
  • THBD protein, human
  • Thrombomodulin
  • Fluvastatin
  • Rosuvastatin Calcium
  • Simvastatin
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III